Intersouth Partners is a venture capital firm based in Durham, North Carolina, that specializes in seed and early-stage investments, primarily within the technology and life sciences sectors. Founded in 1985, the firm has invested in over 100 private companies and manages approximately $780 million across seven venture capital limited partnerships, making it one of the largest venture capital funds in the Southeast. In technology, Intersouth focuses on areas such as software, semiconductors, communications, digital media, clean technology, and security. In the life sciences sector, it typically invests in medical devices, biopharmaceuticals, agricultural biotechnology, and biomaterials. The firm prefers equity investments, often taking a lead role in financing rounds with initial investments ranging from $0.5 million to $8 million, aiming for an average total investment of $12 million per company. Intersouth seeks to exit its investments within two to six years, often taking a board seat in its portfolio companies, and primarily invests in the Southeast corridor from Baltimore to Florida.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Learn to play the music you love in the Zenph Online Education Network (ZOEN). We deliver the perfect match between teachers and students through live online music lessons. Whether you’re looking to learn your favorite song, seeking advice on perfecting your technique or searching for the right music teacher for your kids, taking a live online music lesson from one of the ZOEN’s experienced, nationally renowned music teachers is just a matter of a few clicks! The ZOEN is brought to you by Zenph, Inc. – our award winning Re-Performance® technology was named one of the “Best Ideas of the Year” by The New York Times Magazine and has earned us accolades from music lovers and critics the world over, including multiple GRAMMY® nominations. Based in North Carolina’s Research Triangle Park, we are a venture-backed technology company led by a team of music and software professionals with expertise in music education, consumer software, social gaming and entertainment.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
Zenph Sound Innovations
Series A in 2009
Acquired by Steinway & Sons Inc., January 2015. Zenph Sound Innovations is a developer of musical analysis technology focused on software services and apps related to music. Zenph Sound Innovations offers technology that converts audio recordings into datasets, enabling a virtual artist play re-performances, precisely replicating a musician’s playing in an original recording.
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Bright View Technologies, Inc. specializes in the development of microstructure-based optical films tailored for the global display industry. The company employs patented technologies to create advanced optical film products that enhance performance in various display types, including Plasma, LCD, Rear Projection, Front Projection, and OLED. Additionally, Bright View's engineered optics devices are applicable in other areas such as lighting and LiDAR, allowing clients to achieve improved brightness, efficiency, and uniformity in their display applications. Through its innovative approach, Bright View Technologies aims to meet the evolving needs of the display market.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
nContact, Inc. is a medical device company specializing in the development of innovative solutions for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2005 and based in Morrisville, North Carolina, the company focuses on minimally invasive ablation procedures. Its flagship product, the Numeris Coagulation System with VisiTrax, utilizes a unique combination of suction, perfusion, and radiofrequency energy to create visible, nonconductive lesions on the epicardium of a beating heart. This system has received regulatory approval for use in the United States and holds CE Mark approval in Europe. nContact also offers a range of other devices designed to ensure consistent contact with cardiac tissue, facilitating effective lesion creation. The company has initiated clinical studies to further explore its technology's application in treating atrial fibrillation through both open and closed chest procedures. In 2011, nContact, formerly known as nContact Surgical, became a subsidiary of AtriCure, Inc.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
nContact, Inc. is a medical device company specializing in the development of innovative solutions for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2005 and based in Morrisville, North Carolina, the company focuses on minimally invasive ablation procedures. Its flagship product, the Numeris Coagulation System with VisiTrax, utilizes a unique combination of suction, perfusion, and radiofrequency energy to create visible, nonconductive lesions on the epicardium of a beating heart. This system has received regulatory approval for use in the United States and holds CE Mark approval in Europe. nContact also offers a range of other devices designed to ensure consistent contact with cardiac tissue, facilitating effective lesion creation. The company has initiated clinical studies to further explore its technology's application in treating atrial fibrillation through both open and closed chest procedures. In 2011, nContact, formerly known as nContact Surgical, became a subsidiary of AtriCure, Inc.
Nitronex is a leading developer and manufacturer of gallium nitride-on-silicon (GaN-on-Si) RF power devices, specializing in high-performance semiconductors for various applications. Founded in 1999 by graduates of the wide bandgap program at North Carolina State University, the company is headquartered in Durham, North Carolina. Nitronex focuses on producing GaN-based RF power transistors that serve markets including wireless communications, broadband, and military applications. With a strong commitment to innovation, the company holds 21 patents and has an additional 17 patents pending, highlighting its role as a pioneer in the development of advanced semiconductor technology.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
HexaTech, Inc. specializes in the development and commercialization of advanced semiconductor materials, particularly single-crystalline aluminum nitride (AlN) substrates. Founded in 2001 and headquartered in Morrisville, North Carolina, the company focuses on producing high-quality AlN wafers that are essential for the fabrication of electronic and optoelectronic devices. These substrates support a range of applications, including ultraviolet (UV-C) light emitting diodes and lasers for disinfection and sterilization, as well as devices for biological threat detection and high voltage power conversion. HexaTech's proprietary crystal growth process allows for the production of high-performance semiconductor devices, including high voltage diodes, switches, and radio frequency components, thereby enhancing the efficiency and longevity of electronic systems across various industries, including biotechnology and pharmaceuticals.
6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
TapRoot Systems specializes in providing software products and services tailored for the mobile device market. The company focuses on delivering an embedded mobile analytics solution, which enables businesses to gain insights into user behavior and application performance on mobile platforms. By offering these analytical tools, TapRoot Systems aims to enhance the functionality and usability of mobile applications, helping clients make informed decisions based on data-driven insights.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
Ablatrics, Inc
Venture Round in 2005
Ablatrics, Inc. a medical device company focused on minimally invasive treatments for atrial fibrillation.
Digital Safety Technologies is directly responsible for the manufacture, sales, technical support, and integration of the formerly known Integrian products. The combination of all these attributes allows us to serve and support former Integrian customers, as well as provide advanced solutions to new customers. They have very quickly established DST as a premier supplier of mobile video technology solutions.
SciQuest provides software-as-a-service procurement automation and supplier enablement solutions. It offers Sourcing Manager, an on-demand bid management solution; Eprocurement online, a suite of procurement automation solutions; Materials Management solution that manages on-site stockroom inventory; and Settlement Manager, an invoicing and settlement solution that automates and streamlines receiving, matching, and invoicing processes. The company also provides Spend Analytics, a spend management solution; supplier network and managed services; implementation services for procurement automation; and a Procurement Business Assessment service, which enables life sciences companies to measure, envision, and plan the roadmap for procurement operations. In addition, it offers HigherMarkets Express for Banner, a suite of eprocurement solution that enables schools to realize the benefits of a strategic approach to procurement while increasing the value of existing systems. The company serves education, healthcare, life sciences, and government organizations. SciQuest was formerly known as SciQuest.com and changed its name to SciQuest in 2001. The company was founded in 1995 and is based in Cary, North Carolina.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
TapRoot Systems specializes in providing software products and services tailored for the mobile device market. The company focuses on delivering an embedded mobile analytics solution, which enables businesses to gain insights into user behavior and application performance on mobile platforms. By offering these analytical tools, TapRoot Systems aims to enhance the functionality and usability of mobile applications, helping clients make informed decisions based on data-driven insights.
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoetic stem and progenitor cells derived from bone marrow, peripheral blood or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
Trinity Convergence designs, develops, and licenses VoIP software solutions.
NetOctave
Series B in 2002
NetOctave, Inc., The Network Security Processor Company, builds security processors and security accelerator add-in cards for the SSL, IPsec, and IP Storage markets. NetOctave employs innovative silicon architectures to deliver market-leading system-level performance for OEM manufacturers of network equipment. NetOctave’s security products deliver complete protocol offload at line rates, enabling high-speed performance for encrypted traffic.
Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
Encelle, Inc. has developed novel products fortissue regeneration. The company has developed and patented an injectable biopolymer that is expected to have broad application for multiple therapeutic indications. Product development programs are under way in tendo and bone repair, dermal wound repair, cosmetic surgery, and dental applications.
StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoetic stem and progenitor cells derived from bone marrow, peripheral blood or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.
NetOctave
Series A in 2000
NetOctave, Inc., The Network Security Processor Company, builds security processors and security accelerator add-in cards for the SSL, IPsec, and IP Storage markets. NetOctave employs innovative silicon architectures to deliver market-leading system-level performance for OEM manufacturers of network equipment. NetOctave’s security products deliver complete protocol offload at line rates, enabling high-speed performance for encrypted traffic.
Alerts.com, Inc.
Series B in 2000
Alerts.com remotely monitors Web sites to deliver personalized, persistent search results via wireless devices, interactive voice, text and email. The Alerts.com system offers both content alerting capabilities and delivery of content directly to wireless devices using SMS or WAP protocols. Offered as a service through our partners and through Alerts.com's own Internet site, users request to be notified when specific Web content - like a news story or a product price - satisfies the user's alert parameters. The Alerts.com system provides business-to-business and business-to-consumer markets with a seamless, diligent infrastructure service that helps build and manage customer relationships by delivering information when and where people need it. The service, by exposing and delivering dynamic content notifications, generates qualified repeat visits to partners' sites and serves an indispensable role in opt-in, affinity-based marketing efforts.
Accordant provides its program members with healthcare advice. The service focuses on delivering support for patients with rare, chronic diseases. Its care management solutions comprise of tools and resources of professionals in the healthcare sector. The service also delivers care management services for rare diseases which include health plans, employers, and third party administrators. Accordant is a subsidiary of CVS Caremark. It was founded by Steve Schelhammer and is headquartered in Greensboro, North Carolina.
Alerts.com, Inc.
Series A in 1999
Alerts.com remotely monitors Web sites to deliver personalized, persistent search results via wireless devices, interactive voice, text and email. The Alerts.com system offers both content alerting capabilities and delivery of content directly to wireless devices using SMS or WAP protocols. Offered as a service through our partners and through Alerts.com's own Internet site, users request to be notified when specific Web content - like a news story or a product price - satisfies the user's alert parameters. The Alerts.com system provides business-to-business and business-to-consumer markets with a seamless, diligent infrastructure service that helps build and manage customer relationships by delivering information when and where people need it. The service, by exposing and delivering dynamic content notifications, generates qualified repeat visits to partners' sites and serves an indispensable role in opt-in, affinity-based marketing efforts.
Accipiter offers online advertising solutions and services worldwide. It offers AdManager, an ad management solution that allows to increase targeting capabilities to speed ad delivery and to monitor and control inventory projections in real-time; Ad Trafficking, which provides AdManager hosted clients with outsourced and customized solution to administer the campaign management process; AdMarket, a real-time bid-for-placement technology enabling publishers to operate branded online advertising marketplaces and transact with advertisers who are requesting a pay-per-click pricing model; and Visitor Interest Behavioral Engine, a behavioral targeting solution that delivers promotions and content to interested prospects. Accipiter is based in Raleigh, North Carolina with an additional office in London, United Kingdom.
Accipiter offers online advertising solutions and services worldwide. It offers AdManager, an ad management solution that allows to increase targeting capabilities to speed ad delivery and to monitor and control inventory projections in real-time; Ad Trafficking, which provides AdManager hosted clients with outsourced and customized solution to administer the campaign management process; AdMarket, a real-time bid-for-placement technology enabling publishers to operate branded online advertising marketplaces and transact with advertisers who are requesting a pay-per-click pricing model; and Visitor Interest Behavioral Engine, a behavioral targeting solution that delivers promotions and content to interested prospects. Accipiter is based in Raleigh, North Carolina with an additional office in London, United Kingdom.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.